COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry
Introduction Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are a...
Saved in:
Published in | Annals of hematology Vol. 100; no. 2; pp. 383 - 393 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.02.2021
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction
Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk.
Patients and methods
We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality.
Results
In total, 435 cancer patients were included in our analysis. Commonest age category was 76–85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%,
p
value < 0.001). After adjustments for other risk factors, mortality was comparable.
Conclusion
Comparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions. |
---|---|
AbstractList | IntroductionSince the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk.Patients and methodsWe retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality.ResultsIn total, 435 cancer patients were included in our analysis. Commonest age category was 76–85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%, p value < 0.001). After adjustments for other risk factors, mortality was comparable.ConclusionComparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions. Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk. We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality. In total, 435 cancer patients were included in our analysis. Commonest age category was 76-85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%, p value < 0.001). After adjustments for other risk factors, mortality was comparable. Comparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions. Abstract Introduction Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk. Patients and methods We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality. Results In total, 435 cancer patients were included in our analysis. Commonest age category was 76–85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%, p value < 0.001). After adjustments for other risk factors, mortality was comparable. Conclusion Comparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions. Introduction Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk. Patients and methods We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality. Results In total, 435 cancer patients were included in our analysis. Commonest age category was 76–85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%, p value < 0.001). After adjustments for other risk factors, mortality was comparable. Conclusion Comparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions. |
Author | Lanznaster, J. Dolff, S. Merle, U. Borgmann, S. Isberner, N. Schons, M. Classen, A. Y. Wille, K. Vehreschild, J. J. Grüner, B. Schneider, J. Strauss, R. Hanses, F. Beutel, G. Nadalin, S. von Lilienfeld-Toal, M. Giessen-Jung, C. Köhler, P. Rüthrich, Maria Madeleine Tometten, L. Piepel, C. |
Author_xml | – sequence: 1 givenname: Maria Madeleine orcidid: 0000-0001-7577-181X surname: Rüthrich fullname: Rüthrich, Maria Madeleine email: maria.ruethrich@med.uni-jena.de organization: Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll Institute – sequence: 2 givenname: C. surname: Giessen-Jung fullname: Giessen-Jung, C. organization: Department of Internal Medicine III, Ludwig Maximilian University – sequence: 3 givenname: S. surname: Borgmann fullname: Borgmann, S. organization: Department of Infectious Diseases and Infection Control, Ingolstadt Hospital – sequence: 4 givenname: A. Y. surname: Classen fullname: Classen, A. Y. organization: Department I for Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, German Centre for Infection Research (DZIF), partner site Bonn-Cologne – sequence: 5 givenname: S. surname: Dolff fullname: Dolff, S. organization: Department of Infectious Diseases, University Hospital Essen, University Duisburg Essen – sequence: 6 givenname: B. surname: Grüner fullname: Grüner, B. organization: Section Clinical Infectiology, University Hospital Ulm – sequence: 7 givenname: F. surname: Hanses fullname: Hanses, F. organization: Emergency Department, University Hospital Regensburg – sequence: 8 givenname: N. surname: Isberner fullname: Isberner, N. organization: Department of Internal Medicine II, Division of Infectious Diseases, University Hospital Würzburg – sequence: 9 givenname: P. surname: Köhler fullname: Köhler, P. organization: Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne – sequence: 10 givenname: J. surname: Lanznaster fullname: Lanznaster, J. organization: Department of Internal Medicine II, Passau Hospital – sequence: 11 givenname: U. surname: Merle fullname: Merle, U. organization: Department of Internal Medicine IV, University Hospital Heidelberg – sequence: 12 givenname: S. surname: Nadalin fullname: Nadalin, S. organization: Department of General, Visceral and Transplant Surgery, University Hospital Tübingen – sequence: 13 givenname: C. surname: Piepel fullname: Piepel, C. organization: Hospital Bremen-Center – sequence: 14 givenname: J. surname: Schneider fullname: Schneider, J. organization: Department of Internal Medicine II, Technical University of Munich, School of Medicine, University hospital rechts der Isar, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne – sequence: 15 givenname: M. surname: Schons fullname: Schons, M. organization: Department I for Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne – sequence: 16 givenname: R. surname: Strauss fullname: Strauss, R. organization: Medical Clinic I, University Hospital Erlangen – sequence: 17 givenname: L. surname: Tometten fullname: Tometten, L. organization: Department of Gastroenterology and Infectiology, Hospital Ernst-von-Bergmann – sequence: 18 givenname: J. J. surname: Vehreschild fullname: Vehreschild, J. J. organization: Department I for Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt – sequence: 19 givenname: M. surname: von Lilienfeld-Toal fullname: von Lilienfeld-Toal, M. organization: Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll Institute – sequence: 20 givenname: G. surname: Beutel fullname: Beutel, G. organization: Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School – sequence: 21 givenname: K. surname: Wille fullname: Wille, K. organization: University of Bochum, University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33159569$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1uEzEUhS1URNPCC7BAltiwGbj-mbHNAgmFApUiZVFga3mcO4mriSfYM0jZ8RA8YZ-kDinlZ4E3tny_c66vzxk5iUNEQp4yeMkA1KsMwJWqgEMFUnBdyQdkxsqpglrLEzIDI0xVl3VKznK-BmBcS_6InArBalM3ZkZwvvxy-a5ihoZIvYseE925MWAc82vq-xCDdz31G5ecHzGFPAafqYsrOkyjH7Z48_2Hi-XC9fscMh06Om6QLi6WV1c04boI0v4xedi5PuOTu_2cfH5_8Wn-sVosP1zO3y4qL5UcKy5AtU6rVmuDXatY20qPYJzX0LiGdeA6KXSNzBlQ0JpWoENulAOoV8jFOXlz9N1N7RZXvkyRXG93KWxd2tvBBft3JYaNXQ_frGqkrqUoBi_uDNLwdcI82m3IHvveRRymbLmsteJMyEOv5_-g18OUyjccKGU4F7pRheJHyqch54Td_WMY2EOK9piiLSnanylaWUTP_hzjXvIrtgKII5BLKa4x_e79H9tbrF6rCQ |
CitedBy_id | crossref_primary_10_1371_journal_pone_0271822 crossref_primary_10_1016_j_ejca_2021_01_033 crossref_primary_10_7554_eLife_81127 crossref_primary_10_1007_s00292_021_00924_x crossref_primary_10_3390_ctn6010006 crossref_primary_10_1007_s00520_023_08135_1 crossref_primary_10_3389_fmed_2024_1332716 crossref_primary_10_1080_16078454_2022_2089830 crossref_primary_10_1007_s00520_022_07028_z crossref_primary_10_1093_trstmh_trac015 crossref_primary_10_1007_s00520_021_06149_1 crossref_primary_10_3389_fimmu_2022_899930 crossref_primary_10_1016_j_vaccine_2021_12_046 crossref_primary_10_1002_cam4_7032 crossref_primary_10_5501_wjv_v10_i6_312 crossref_primary_10_3390_cancers13153883 crossref_primary_10_3390_jcm10173855 crossref_primary_10_1080_21645515_2021_1943988 crossref_primary_10_56061_fbujohs_1226762 crossref_primary_10_1001_jamanetworkopen_2022_10880 crossref_primary_10_1186_s12879_021_07019_1 crossref_primary_10_3390_vaccines10050738 crossref_primary_10_1055_a_1392_4142 crossref_primary_10_1016_j_ejca_2022_11_030 crossref_primary_10_1200_JCO_21_01074 crossref_primary_10_1002_onco_13861 crossref_primary_10_1055_s_0042_1742440 crossref_primary_10_3389_fpubh_2024_1323481 crossref_primary_10_1002_ueg2_12165 crossref_primary_10_1007_s00432_022_03961_y crossref_primary_10_1038_s41416_021_01324_x crossref_primary_10_3390_microorganisms11020319 crossref_primary_10_1371_journal_pone_0267584 crossref_primary_10_1177_03008916211073771 crossref_primary_10_1007_s00432_022_04099_7 crossref_primary_10_3389_fmed_2021_736109 crossref_primary_10_1016_j_critrevonc_2021_103365 crossref_primary_10_1111_ejh_13926 crossref_primary_10_5144_0256_4947_2023_1 crossref_primary_10_1002_cam4_4582 crossref_primary_10_1007_s00761_021_00972_1 crossref_primary_10_1080_14787210_2024_2309998 crossref_primary_10_1080_07357907_2022_2075376 crossref_primary_10_3390_cancers14153711 crossref_primary_10_1186_s13053_023_00248_2 crossref_primary_10_1007_s10147_023_02311_3 crossref_primary_10_56083_RCV3N10_002 crossref_primary_10_1016_j_resmer_2024_101093 crossref_primary_10_1360_nso_20220004 crossref_primary_10_1007_s00520_022_07098_z crossref_primary_10_1007_s00432_023_04961_2 crossref_primary_10_3390_cancers14184497 crossref_primary_10_7759_cureus_51310 crossref_primary_10_1055_a_1348_3454 crossref_primary_10_17650_1818_8346_2021_16_2_70_80 crossref_primary_10_1055_a_1655_8705 crossref_primary_10_1016_S1470_2045_21_00454_X crossref_primary_10_17749_2313_7347_ob_gyn_rep_2024_519 crossref_primary_10_3390_cancers15010222 crossref_primary_10_1002_ueg2_12103 crossref_primary_10_1038_s41419_022_05548_4 crossref_primary_10_1007_s15010_022_01869_w crossref_primary_10_1007_s11764_022_01236_6 crossref_primary_10_1158_2159_8290_CD_21_0210 crossref_primary_10_4291_wjgp_v13_i5_157 crossref_primary_10_1097_HS9_0000000000000651 crossref_primary_10_1016_j_ccm_2022_11_014 crossref_primary_10_3390_pathogens11050563 crossref_primary_10_1001_jamanetworkopen_2022_51165 crossref_primary_10_1200_GO_22_00043 crossref_primary_10_1097_MD_0000000000034082 crossref_primary_10_3390_cancers13184621 crossref_primary_10_1002_cam4_6781 crossref_primary_10_1002_cnr2_1678 crossref_primary_10_1038_s41409_023_02096_z crossref_primary_10_1002_ajh_26209 crossref_primary_10_1007_s15010_022_01852_5 crossref_primary_10_7554_eLife_74634 crossref_primary_10_1007_s00277_022_04866_z crossref_primary_10_3389_fonc_2022_1029325 crossref_primary_10_3389_fonc_2023_1217805 crossref_primary_10_1016_j_heliyon_2023_e22426 crossref_primary_10_1097_MPH_0000000000002588 crossref_primary_10_3389_fonc_2021_662211 crossref_primary_10_1007_s43069_022_00191_3 crossref_primary_10_12688_f1000research_76143_1 crossref_primary_10_1002_cam4_4379 crossref_primary_10_1007_s12254_022_00814_9 crossref_primary_10_1631_jzus_B2100151 crossref_primary_10_3390_curroncol29020098 crossref_primary_10_4103_jcrt_jcrt_464_21 crossref_primary_10_1155_2022_8973449 crossref_primary_10_1038_s41571_022_00610_8 crossref_primary_10_54033_cadpedv21n1_188 crossref_primary_10_1001_jamaoncol_2021_5148 crossref_primary_10_3390_vaccines11020486 crossref_primary_10_1002_cam4_4023 crossref_primary_10_3390_microorganisms10122490 crossref_primary_10_1001_jamanetworkopen_2022_0130 crossref_primary_10_1159_000525802 crossref_primary_10_3389_fendo_2022_971687 crossref_primary_10_1111_cas_15434 crossref_primary_10_3390_ijerph19159041 crossref_primary_10_1016_j_clbc_2021_12_005 crossref_primary_10_1016_j_ctarc_2021_100425 crossref_primary_10_17749_2313_7347_ob_gyn_rep_2021_249 crossref_primary_10_3390_cancers13122917 crossref_primary_10_3390_cancers14153746 crossref_primary_10_3390_jcm10194606 |
Cites_doi | 10.1016/j.jaut.2020.102433 10.1038/s41375-020-0836-7 10.1016/j.eclinm.2020.100519 10.1158/2159-8290.CD-20-0516 10.1016/S1470-2045(20)30096-6 10.1136/esmoopen-2020-000947 10.1001/jama.2020.6775 10.1016/S0140-6736(20)31173-9 10.1016/j.annonc.2020.03.296 10.1016/S0140-6736(20)31187-9 10.1186/s12916-020-01649-z 10.1016/S1470-2045(20)30309-0 10.1001/jama.2020.1585 10.1016/S2213-2600(20)30079-5 10.1007/s00134-012-2627-8 10.1158/2159-8290.CD-20-0422 10.1007/s42399-020-00363-4 10.3324/haematol.2020.262758 10.1007/s15010-020-01499-0 10.1002/cam4.3460 |
ContentType | Journal Article |
Copyright | The Author(s) 2020 The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
CorporateAuthor | LEOSS Study Group on behalf of the LEOSS Study Group |
CorporateAuthor_xml | – name: LEOSS Study Group – name: on behalf of the LEOSS Study Group |
DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1007/s00277-020-04328-4 |
DatabaseName | SpringerOpen Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Eastern Edition MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: C6C name: Springer_OA刊 url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 7X7 name: Health Medical collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1432-0584 |
EndPage | 393 |
ExternalDocumentID | 10_1007_s00277_020_04328_4 33159569 |
Genre | Multicenter Study Journal Article |
GeographicLocations | Europe |
GeographicLocations_xml | – name: Europe |
GrantInformation_xml | – fundername: Universitätsklinikum Jena (8979) – fundername: ; |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C -~X .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFFNX AFJLC AFKRA AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z5O Z7S Z7U Z7X Z82 Z83 Z86 Z87 Z8N Z8O Z8V Z8W Z91 ZMTXR ZOVNA ZXP ~EX ~KM AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7XB 8FK K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c474t-2307ba87b889efb71bb4ce09ac806a61f0af4385e1a9070b9b3eae297a005de23 |
IEDL.DBID | 7X7 |
ISSN | 0939-5555 |
IngestDate | Tue Sep 17 21:17:00 EDT 2024 Fri Aug 16 03:03:48 EDT 2024 Thu Oct 10 17:00:37 EDT 2024 Thu Sep 12 19:40:22 EDT 2024 Wed Oct 16 00:44:47 EDT 2024 Sat Dec 16 12:03:39 EST 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | COVID-19 SARS-CoV-2 Cancer patients Cohort study Adjusted analysis Pandemic LEOSS |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c474t-2307ba87b889efb71bb4ce09ac806a61f0af4385e1a9070b9b3eae297a005de23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-7577-181X |
OpenAccessLink | http://link.springer.com/10.1007/s00277-020-04328-4 |
PMID | 33159569 |
PQID | 2479223867 |
PQPubID | 54039 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7648543 proquest_miscellaneous_2458721342 proquest_journals_2479223867 crossref_primary_10_1007_s00277_020_04328_4 pubmed_primary_33159569 springer_journals_10_1007_s00277_020_04328_4 |
PublicationCentury | 2000 |
PublicationDate | 2021-02-01 |
PublicationDateYYYYMMDD | 2021-02-01 |
PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Berlin |
PublicationTitle | Annals of hematology |
PublicationTitleAbbrev | Ann Hematol |
PublicationTitleAlternate | Ann Hematol |
PublicationYear | 2021 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
References | CR2 Dai, Liu, Liu, Zhou, Li, Chen, Zhang, You, Wu, Zheng, Xiong, Xiong, Wang, Chen, Xiong, Zhang, Peng, Ge, Zhen, Yu, Wang, Wang, Liu, Chen, Mei, Gao, Li, Gan, He, Li, Shi, Qi, Yang, Tenen, Chai, Mucci, Santillana, Cai (CR5) 2020; 10 Rothan, Byrareddy (CR1) 2020; 109 Wang, Hu, Hu, Zhu, Liu, Zhang, Wang, Xiang, Cheng, Xiong, Zhao, Li, Wang, Peng (CR3) 2020; 323 CR6 Tian, Yuan, Xiao, Zhong, Yang, Liu, Cai, Lu, Wang, Wang, Liu, Cheng, Wang, Zhang, Wang, Niu, Yao, Deng, Zhou, Wei, Li, Chen, Chen, Yang, Wu, Fan, Shu, Hu, Wang, Yang, Liu, Miao, Wang (CR23) 2020; 21 Yang, Yu, Xu, Shu, Xia, Liu, Wu, Zhang, Yu, Fang, Yu, Wang, Pan, Zou, Yuan, Shang (CR4) 2020; 8 CR19 Park, Chidharla, Mehta, Sun, Wulff-Burchfield, Kasi (CR10) 2020; 26 Lee, Cazier, Angelis, Arnold, Bisht, Campton, Chackathayil, Cheng, Curley, Fittall, Freeman-Mills, Gennatas, Goel, Hartley, Hughes, Kerr, Lee, Lee, McGrath, Middleton, Murugaesu, Newsom-Davis, Okines, Olsson-Brown, Palles, Pan, Pettengell, Powles, Protheroe, Purshouse, Sharma-Oates, Sivakumar, Smith, Starkey, Turnbull, Várnai, Yousaf, Kerr, Middleton (CR12) 2020; 395 CR18 de Azambuja, Brandão, Wildiers, Laenen, Aspeslagh, Fontaine, Collignon, Lybaert, Verheezen, Rutten, Vuylsteke, Goeminne, Demey, van Beckhoven, Deblonde, Rottey, Geukens, Punie (CR24) 2020; 5 CR16 CR14 CR11 CR21 Rhodes, Ferdinande, Flaatten, Guidet, Metnitz, Moreno (CR22) 2012; 38 Mehta, Goel, Kabarriti, Cole, Goldfinger, Acuna-Villaorduna, Pradhan, Thota, Reissman, Sparano, Gartrell, Smith, Ohri, Garg, Racine, Kalnicki, Perez-Soler, Halmos, Verma (CR13) 2020; 10 Zhang, Zhu, Xie, Wang, Wang, Chen, Jia, Guan, Peng, Chen, Peng, Zhang, Chu, Shen, Wang, Xu, Zhao, Zhou (CR17) 2020; 31 Liang, Guan, Chen, Wang, Li, Xu, Li, Ai, Lu, Liang, Li, He (CR7) 2020; 21 He, Chen, Chen, Yuan, Fang, Chen, Wu, Liang, Lu, Ma, Li, Wang, Chen, Li, Gale (CR8) 2020; 34 Kuderer, Choueiri, Shah, Shyr, Rubinstein, Rivera, Shete, Hsu, Desai, de Lima Lopes, Grivas, Painter, Peters, Thompson, Bakouny, Batist, Bekaii-Saab, Bilen, Bouganim, Larroya, Castellano, del Prete, Doroshow, Egan, Elkrief, Farmakiotis, Flora, Galsky, Glover, Griffiths, Gulati, Gupta, Hafez, Halfdanarson, Hawley, Hsu, Kasi, Khaki, Lemmon, Lewis, Logan, Masters, McKay, Mesa, Morgans, Mulcahy, Panagiotou, Peddi, Pennell, Reynolds, Rosen, Rosovsky, Salazar, Schmidt, Shah, Shaya, Steinharter, Stockerl-Goldstein, Subbiah, Vinh, Wehbe, Weissmann, Wu, Wulff-Burchfield, Xie, Yeh, Yu, Zhou, Zubiri, Mishra, Lyman, Rini, Warner, Abidi, Acoba, Agarwal, Ahmad, Ajmera, Altman, Angevine, Azad, Bar, Bardia, Barnholtz-Sloan, Barrow, Bashir, Belenkaya, Berg, Bernicker, Bestvina, Bishnoi, Boland, Bonnen, Bouchard, Bowles, Busser, Cabal, Caimi, Carducci, Casulo, Chen, Clement, Chism, Cook, Curran, Daher, Dailey, Dahiya, Deeken, Demetri, DiLullo, Duma, Elias, Faller, Fecher, Feldman, Friese, Fu, Fu, Futreal, Gainor, Garcia, Gill, Gillaspie, Giordano, Glace, Grothey, Gulati, Gurley, Halmos, Herbst, Hershman, Hoskins, Jain, Jabbour, Jha, Johnson, Joshi, Kelleher, Kharofa, Khan, Knoble, Koshkin, Kulkarni, Lammers, Leighton, Lewis, Li, Li, Lo, Loaiza-Bonilla, LoRusso, Low, Lustberg, Mahadevan, Mansoor, Marcum, Markham, Handy Marshall, Mashru, Matar, McNair, McWeeney, Mehnert, Menendez, Menon, Messmer, Monahan, Mushtaq, Nagaraj, Nagle, Naidoo, Nakayama, Narayan, Nelson, Nemecek, Nguyen, Nuzzo, Oberstein, Olszewski, Owenby, Pasquinelli, Philip, Prabhakaran, Puc, Ramirez, Rathmann, Revankar, Rho, Rhodes, Rice, Riely, Riess, Rink, Robilotti, Rosenstein, Routy, Rovito, Saif, Sanyal, Schapira, Schwartz, Serrano, Shah, Shah, Shaw, Shergill, Shouse, Soares, Solorzano, Srivastava, Stauffer, Stover, Stratton, Stratton, Subbiah, Tamimi, Tannir, Topaloglu, van Allen, van Loon, Vega-Luna, Venepalli, Verma, Vikas, Wall, Weinstein, Weiss, Wise-Draper, Wood, Xu, Yackzan, Zacks, Zhang, Zimmer, West (CR9) 2020; 395 Richardson, Hirsch, Narasimhan, Crawford, McGinn, Davidson, Barnaby, Becker, Chelico, Cohen, Cookingham, Coppa, Diefenbach, Dominello, Duer-Hefele, Falzon, Gitlin, Hajizadeh, Harvin, Hirschwerk, Kim, Kozel, Marrast, Mogavero, Osorio, Qiu, Zanos (CR20) 2020; 323 Joharatnam-Hogan, Khan (CR15) 2020; 18 N Joharatnam-Hogan (4328_CR15) 2020; 18 4328_CR6 V Mehta (4328_CR13) 2020; 10 4328_CR2 4328_CR11 4328_CR21 E de Azambuja (4328_CR24) 2020; 5 HA Rothan (4328_CR1) 2020; 109 NM Kuderer (4328_CR9) 2020; 395 4328_CR16 A Rhodes (4328_CR22) 2012; 38 D Wang (4328_CR3) 2020; 323 4328_CR14 4328_CR19 S Richardson (4328_CR20) 2020; 323 4328_CR18 X Yang (4328_CR4) 2020; 8 R Park (4328_CR10) 2020; 26 L Zhang (4328_CR17) 2020; 31 W Liang (4328_CR7) 2020; 21 W He (4328_CR8) 2020; 34 M Dai (4328_CR5) 2020; 10 LY Lee (4328_CR12) 2020; 395 J Tian (4328_CR23) 2020; 21 |
References_xml | – ident: CR21 – ident: CR19 – ident: CR18 – ident: CR14 – ident: CR2 – ident: CR16 – volume: 109 start-page: 102433 year: 2020 ident: CR1 article-title: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak publication-title: J Autoimmun doi: 10.1016/j.jaut.2020.102433 contributor: fullname: Byrareddy – volume: 34 start-page: 1637 issue: 6 year: 2020 end-page: 1645 ident: CR8 article-title: COVID-19 in persons with haematological cancers publication-title: Leukemia doi: 10.1038/s41375-020-0836-7 contributor: fullname: Gale – volume: 26 start-page: 100519 year: 2020 ident: CR10 article-title: Sex-bias in COVID-19-associated illness severity and mortality in cancer patients: a systematic review and meta-analysis publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2020.100519 contributor: fullname: Kasi – ident: CR11 – volume: 10 start-page: 935 issue: 7 year: 2020 end-page: 941 ident: CR13 article-title: Case fatality rate of cancer patients with COVID-19 in a New York Hospital System publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-0516 contributor: fullname: Verma – volume: 21 start-page: 335 issue: 3 year: 2020 end-page: 337 ident: CR7 article-title: Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30096-6 contributor: fullname: He – volume: 5 start-page: e000947 issue: 5 year: 2020 ident: CR24 article-title: Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis publication-title: ESMO Open doi: 10.1136/esmoopen-2020-000947 contributor: fullname: Punie – volume: 323 start-page: 2052 year: 2020 end-page: 2059 ident: CR20 article-title: Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area publication-title: JAMA doi: 10.1001/jama.2020.6775 contributor: fullname: Zanos – volume: 395 start-page: 1919 issue: 10241 year: 2020 end-page: 1926 ident: CR12 article-title: COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(20)31173-9 contributor: fullname: Middleton – volume: 31 start-page: 894 issue: 7 year: 2020 end-page: 901 ident: CR17 article-title: Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.03.296 contributor: fullname: Zhou – ident: CR6 – volume: 395 start-page: 1907 issue: 10241 year: 2020 end-page: 1918 ident: CR9 article-title: Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study publication-title: Lancet doi: 10.1016/S0140-6736(20)31187-9 contributor: fullname: West – volume: 18 start-page: 182 issue: 1 year: 2020 ident: CR15 article-title: COVID-19 cancer conundrum-evidence driving decisions or the lack of it? publication-title: BMC Med doi: 10.1186/s12916-020-01649-z contributor: fullname: Khan – volume: 21 start-page: 893 issue: 7 year: 2020 end-page: 903 ident: CR23 article-title: Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30309-0 contributor: fullname: Wang – volume: 323 start-page: 1061 issue: 11 year: 2020 end-page: 1069 ident: CR3 article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China publication-title: JAMA doi: 10.1001/jama.2020.1585 contributor: fullname: Peng – volume: 8 start-page: 475 issue: 5 year: 2020 end-page: 481 ident: CR4 article-title: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30079-5 contributor: fullname: Shang – volume: 10 start-page: 783 issue: 6 year: 2020 end-page: 791 ident: CR5 article-title: Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak publication-title: Cancer Discov contributor: fullname: Cai – volume: 38 start-page: 1647 issue: 10 year: 2012 end-page: 1653 ident: CR22 article-title: The variability of critical care bed numbers in Europe publication-title: Intensive Care Med doi: 10.1007/s00134-012-2627-8 contributor: fullname: Moreno – ident: 4328_CR6 – ident: 4328_CR19 – volume: 21 start-page: 335 issue: 3 year: 2020 ident: 4328_CR7 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30096-6 contributor: fullname: W Liang – ident: 4328_CR16 – volume: 31 start-page: 894 issue: 7 year: 2020 ident: 4328_CR17 publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.03.296 contributor: fullname: L Zhang – volume: 323 start-page: 2052 year: 2020 ident: 4328_CR20 publication-title: JAMA doi: 10.1001/jama.2020.6775 contributor: fullname: S Richardson – volume: 38 start-page: 1647 issue: 10 year: 2012 ident: 4328_CR22 publication-title: Intensive Care Med doi: 10.1007/s00134-012-2627-8 contributor: fullname: A Rhodes – volume: 10 start-page: 783 issue: 6 year: 2020 ident: 4328_CR5 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-0422 contributor: fullname: M Dai – volume: 323 start-page: 1061 issue: 11 year: 2020 ident: 4328_CR3 publication-title: JAMA doi: 10.1001/jama.2020.1585 contributor: fullname: D Wang – ident: 4328_CR11 doi: 10.1007/s42399-020-00363-4 – ident: 4328_CR18 doi: 10.3324/haematol.2020.262758 – ident: 4328_CR21 doi: 10.1007/s15010-020-01499-0 – volume: 109 start-page: 102433 year: 2020 ident: 4328_CR1 publication-title: J Autoimmun doi: 10.1016/j.jaut.2020.102433 contributor: fullname: HA Rothan – volume: 18 start-page: 182 issue: 1 year: 2020 ident: 4328_CR15 publication-title: BMC Med doi: 10.1186/s12916-020-01649-z contributor: fullname: N Joharatnam-Hogan – volume: 395 start-page: 1907 issue: 10241 year: 2020 ident: 4328_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(20)31187-9 contributor: fullname: NM Kuderer – volume: 21 start-page: 893 issue: 7 year: 2020 ident: 4328_CR23 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30309-0 contributor: fullname: J Tian – volume: 8 start-page: 475 issue: 5 year: 2020 ident: 4328_CR4 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30079-5 contributor: fullname: X Yang – volume: 10 start-page: 935 issue: 7 year: 2020 ident: 4328_CR13 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-0516 contributor: fullname: V Mehta – volume: 34 start-page: 1637 issue: 6 year: 2020 ident: 4328_CR8 publication-title: Leukemia doi: 10.1038/s41375-020-0836-7 contributor: fullname: W He – volume: 26 start-page: 100519 year: 2020 ident: 4328_CR10 publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2020.100519 contributor: fullname: R Park – ident: 4328_CR14 doi: 10.1002/cam4.3460 – ident: 4328_CR2 – volume: 5 start-page: e000947 issue: 5 year: 2020 ident: 4328_CR24 publication-title: ESMO Open doi: 10.1136/esmoopen-2020-000947 contributor: fullname: E de Azambuja – volume: 395 start-page: 1919 issue: 10241 year: 2020 ident: 4328_CR12 publication-title: Lancet doi: 10.1016/S0140-6736(20)31173-9 contributor: fullname: LY Lee |
SSID | ssj0012842 |
Score | 2.635633 |
Snippet | Introduction
Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of... Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer... Abstract Introduction Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an... IntroductionSince the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of... INTRODUCTIONSince the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of... |
SourceID | pubmedcentral proquest crossref pubmed springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 383 |
SubjectTerms | Adolescent Adult Age Aged Aged, 80 and over Cancer Cohort analysis Comorbidity Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 - virology Europe - epidemiology Female Hematology Hospital Mortality Hospitalization - statistics & numerical data Humans Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Mortality Neoplasms - epidemiology Neoplasms - therapy Oncology Original Original Article Outcome Assessment, Health Care - methods Outcome Assessment, Health Care - statistics & numerical data Pandemics Registries - statistics & numerical data Retrospective Studies SARS-CoV-2 - isolation & purification SARS-CoV-2 - physiology Severe acute respiratory syndrome coronavirus 2 Young Adult |
SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB5RkFAvqJQ-QgG5EjdqyYnt2O4N8RBUBQ6wiFvkcRyVSxbB7p0fwS_kl9T2JkHL40COseUkM358k5n5BmA7gI5cK8-oZYWlAmVOkcdyLwqVF85g7eKvgZPT8mgk_lzJq6c87hTs3nsk00Y95Lqx5G2M1k5kkdNUfIClCB6ixTUqdgfXQdhvk-vAcENluLpMmdfHmD-NXkDMl5GSz9yl6RQ6_AQrHXwkuzN9r8KCbz_D8knnIF8Dv3d2ebxPc0OuW-KiRm9JR51695v0aZDEzdM0E9vWZDydBEn4x_sH24YbM64SMm5IgIjk78HZ-TmJVRxicbgvMDo8uNg7ol0lBeqEEhMao73RaoVaG9-gyhGF88xYp1lpy7xhthFcS5_bYCwzNMi99YVRNizS2hf8Kyy249Z_ByJrK0vtmKuDLSNrYRE5IkNswvii8Rns9BKtbmaEGdVAjZzkXwX5V0n-lchgoxd61S2eu6oQygTUokuVwc-hOUz76MuwrR9PYx-pVWSjKzL4NtPR8DjOA0aTpclAzWlv6BAptedb2ut_iVpblUJLwTP41ev56bXe_or193X_AR-LGBmTYr83YHFyO_WbAdpMcCtN5f-G-vFD priority: 102 providerName: Springer Nature |
Title | COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry |
URI | https://link.springer.com/article/10.1007/s00277-020-04328-4 https://www.ncbi.nlm.nih.gov/pubmed/33159569 https://www.proquest.com/docview/2479223867 https://search.proquest.com/docview/2458721342 https://pubmed.ncbi.nlm.nih.gov/PMC7648543 |
Volume | 100 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BKyEuiDehDxmJG1jkYcc2F7S77FIe3SLKou0psh1H9JK03d17f0R_Ib-kY2-Saqkgh1iKrSSesT0znvE3AK9R6UikcDHVcaopMzyhJvPpXoQRjlllSuu3Bg6n-cGMfZnzebvhtmjDKrs1MSzUZWP9Hvm7lAmFokzm4sPZOfVZo7x3tU2hcRe2kxSVCRzPYt4bXH7pDV4ElSnK8WoPzYSjc3FwXnrjyYPSSco2BdMtbfN20ORfntMgkCYP4UGrSZLBmvWP4I6rH8O9w9ZX_gTc6OjX5480UeS0JtYz94K0KKqL96Q7EUnsJmIz0XVJmtUSieL-XF7pGh-sYUtIUxHUFsm38dHxMfEJHXyeuKcwm4x_jg5om1SBWibYkvrAb6OlMFIqVxmRGMOsi5W2Ms51nlSxrlgmuUs02s2xUSZz2qVKaJyvpUuzZ7BVN7V7AYSXmufSxrZEs4aXTBuTGRMbU-H7WeUieNNRtDhbY2cUPUpyoH-B9C8C_QsWwW5H9KKdR4vihusRvOqrcQZ4t4auXbPybbgUHpgujeD5mkf957IM1TWeqwjEBvf6Bh5de7OmPv0dULZFziRnWQRvOz7f_Na_e_Hy_73YgfupD4oJYd-7sLW8WLk91GqWZj8M3X3YHkyGw6kvP518HWM5HE-__8DaUT7C-ywdXAOAevtM |
link.rule.ids | 230,315,786,790,891,12083,21416,27955,27956,31752,31753,33777,33778,41114,41153,41556,42183,42222,42625,43343,43838,51609,52144,52267,74100,74657 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwEB3BVgIuiM8SKGAkbmDhJHZsc0FQttrC7hbRFvUWeRxH7SVpu7t3fgS_kF-CnXVSLRXkGFtJ_Ca2x37jNwCvvdORKukYNSwzlKNIKeYh3YtE6bjVWNmwNTCbF5Nj_uVEnMQNt0UMq-zHxG6grlob9sjfZVxqP5WpQn44v6Aha1RgV2MKjZuwFSQ31Qi2Po3n374PPIIffDseQeeaCn_FYzPd4TnW0Zdh-RRk6RTlm1PTNX_zetjkX9xpNyXt3YO70ZckH9fGvw83XPMAbs0iW_4Q3O7Bj_3PNNXkrCE2mPeSRB3VxXvSn4kkdlOzmZimIu1q6WFxv3_-Mo2_sRYuIW1NvL9IpuODw0MSUjqETHGP4HhvfLQ7oTGtArVc8iUNod9olESltKtRpojcOqaNVawwRVozU3s0hUuNXzkz1Jg74zItje-xlcvyxzBq2sY9ASIqIwplma38wkZU3CDmiAyx9s_ntUvgTY9oeb5WzygHneQO_9LjX3b4lzyBnR70MvakRXll9wReDcW-DwRiwzSuXYU6QskgTZclsL220fC6PPcOmyh0AnLDekOFoK-9WdKcnXY627LgSvA8gbe9na8-69-tePr_VryE25Oj2bSc7s-_PoM7WQiR6YLAd2C0vFy5597HWeKL-CP_AYau-Tg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTtwwEB4VkBCXiv6SQltX6q21cGI7tnupWtgVUFhQKRW3yHYclUtC2d17H6JP2Cep7XWCtqjkmFhJPDO2Z_yNvwF4652OXApHsCaFxszwHBsayr0IIxyzytQ2bA2cTMqDC3Z0yS9T_tM0pVX2c2KcqOvOhj3y3YIJ5ZcyWYrdJqVFnO2PP17_xKGCVEBaUzmNFVgTrOQ-EFv7PJqcfR0wBT8RR0xBUYW5v9IRmniQjkQoM4RSgaJOYra8TN3xPe-mUP6Do8blabwJD5NfiT4tDOERPHDtY1g_Scj5E3B7p98P93Gu0FWLbFD1DUqcqtMPqD8fiewyfzPSbY26-cyLyP359Vu3_saCxAR1DfK-IzoenZ6fo1DeIVSNewoX49G3vQOcSixgywSb4ZAGbrQURkrlGiNyY5h1RGkrSanLvCG6YVRyl2sfRROjDHXaFUpoP3prV9BnsNp2rdsCxGvNS2mJrX2Qw2umjaHGEGMa_37WuAze9RKtrhdMGtXAmRzlX3n5V1H-Fctgpxd6lUbVtLq1gQzeDI_9eAggh25dNw9tuBSBpq7I4PlCR8PnKPXOGy9VBmJJe0ODwLW9_KS9-hE5t0XJJGc0g_e9nm9_6_-9eHF_L17Durfh6vhw8mUbNoqQLRPzwXdgdXYzdy-9uzMzr5Id_wU-3f1s |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+in+cancer+patients%3A+clinical+characteristics+and+outcome-an+analysis+of+the+LEOSS+registry&rft.jtitle=Annals+of+hematology&rft.au=R%C3%BCthrich%2C+Maria+Madeleine&rft.au=Giessen-Jung%2C+C&rft.au=Borgmann%2C+S&rft.au=Classen%2C+A+Y&rft.date=2021-02-01&rft.eissn=1432-0584&rft.volume=100&rft.issue=2&rft.spage=383&rft.epage=393&rft_id=info:doi/10.1007%2Fs00277-020-04328-4&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0939-5555&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0939-5555&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0939-5555&client=summon |